With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

A catalyst for technology-based economic development in life sciences . In 1984, three of North Carolina’s largest ...